spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Novartis Oncology 

 HSMN NewsFeed - 6 Apr 2022
FDA approves Novartis Vijoice(R) (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Oct 2021
Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Sep 2021
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Aug 2020
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Feb 2020
Ichnos Expands Leadership Team With Appointment Of Gabriela Gruia, M.D. As Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2019
Anixa Biosciences Names Novartis Executive Dr. Emanuele Ostuni to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Oct 2019
Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jan 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2017
Bayer Expands Oncology Organization with Two New Leadership Team Appointments
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 May 2017
Churchill Pharmaceuticals Expands Commercial Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2017
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Sep 2016
Neon Therapeutics Appoints Oncology Veteran Hugh O’Dowd to Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Aug 2016
Novartis CDK4/6 Inhibitor LEE011 (Ribociclib) Receives FDA Breakthrough Therapy Designation as First-Line Treatment for HR+/HER2- Advanced Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jul 2015
FDA approves Novartis drug Odomzo(R) (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jan 2015
bioTheranostics Appoints Key Executives to Leadership Team
Diagnostics Personalized Medicine Oncology Personnel
 HSMN NewsFeed - 17 Dec 2014
Inovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
Biopharmaceuticlas Oncology Personnel
 HSMN NewsFeed - 16 Dec 2014
Novartis gains FDA approval for Signifor(R) LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jun 2014
Versartis Appoints Endocrinologist Bert Bakker, MD, PhD, as Senior Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jan 2014
Incyte Names Hervé Hoppenot President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Sep 2013
Vital Therapies, Inc. Expands Executive Team
Devices Regenerative Medicine Personnel
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Feb 2013
Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, Global Research & Development and Technical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Aug 2012
Polynoma Announces Appointment of New Members to Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2011
Viamet Pharmaceuticals Appoints Former Novartis Executive Marc Rudoltz, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2011
Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2010
Novartis Drug Afinitor(R) Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Biopharmaceuticals
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2010
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2009
Novartis Tasigna(R) Trial Shows Superior Results to Gleevec(R) in Patients With Early-Stage Chronic Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2009
Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2009
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Aug 2009
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Biopharmaceuticals Onology
 HSMN NewsFeed - 2 Jul 2009
CombinatoRx and Neuromed Sign Merger Agreement
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 8 May 2009
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2008
Femara(R) (letrozole) FIRST Aromatase Inhibitor to Indicate Overall Survival Benefit Versus tamoxifen When Taken for Five Years After Breast Cancer Surgery
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2008
Molecular Insight Pharmaceuticals, Inc. Adds Four Healthcare Industry Experts to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Mar 2008
Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Apr 2007
Newly Published Study Reveals Femara(R) Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2006
Gleevec(R) Sets New Treatment Standard in Chronic Myeloid Leukemia With High Overall Survival, Increasing Response and Decreasing Progression
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
NICE Initial Recommendation: One Step Closer to Backing Aromatase Inhibitor Treatment for Women With Early Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2006
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 38

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 38 additional stories matching:
Novartis Oncology
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.